Evidence map›Paper›PMID 41843166›Full record

ArticleAnnals of hematology2026

TET2 germline mutation in a patient with sequential lymphoid malignancies: a novel case report.

Xia Mao, Kefeng Shen, Jin Wang, Zhiqiong Wang, Qilin Ao, Chunyan Wang, Min Xiao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xia Mao *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China.
Kefeng Shen *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China.
Jin WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China.
Zhiqiong WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China.
Qilin AoInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chunyan WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China. wcytjmu@163.com.
Min XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China. xiaomin@tjh.tjmu.edu.cn.

Funding

the National Natural Science Foundation of China No.82270203
6 · The paper itself

Abstract

We report a case of a 30-year-old male patient with a germline heterozygous TET2 R1354fs mutation, who successively developed three distinct lymphoid malignancies: mixed cellularity classical Hodgkin lymphoma (MCCHL), angioimmunoblastic T-cell lymphoma (AITL), and T-cell acute lymphoblastic leukemia (T-ALL). Sequencing analysis of the oral mucosa and bone marrow specimens during the remission phase confirmed the germline origin of the TET2 mutation. This represents the first documented case of the sequential transformation across three distinct lymphoid malignancies attributable to a germline TET2 mutation, underscoring its pivotal role in lymphomagenesis and clonal evolution.

Indexed as

DNA-Binding ProteinsGerm-Line MutationHodgkin DiseaseImmunoblastic LymphadenopathyPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene ProteinsAdultDioxygenasesHumansMaleDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanAngioimmunoblastic T-cell lymphomaMixed cellularity classical hodgkin lymphomaSequential lymphoid malignanciesT-cell acute lymphoblastic leukemiaTET2 germline mutation

Identifiers

PMID41843166
PMCPMC12995931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.